As CEO, Dr Jones will lead Resyca’s next phase of growth, expanding strategic collaborations with global pharmaceutical and biotech partners and advancing its soft mist inhaler and nasal spray platforms. Her focus will be on enabling more efficient, patient-friendly drug delivery and strengthening Resyca’s position as a trusted partner in integrated drug–device combination development.

Dr Jones brings more than 20 years of executive leadership experience driving commercial growth in life sciences technology companies. She has guided organisations through international expansion, strategic partnerships, and technology platform scaling to deliver sustained revenue growth. She joins Resyca from Proveris Scientific, where she led commercial strategy across EMEA and India and played a pivotal role in advancing the global adoption of aerosol and spray characterisation technologies. She is widely recognised for her expertise in understanding the complexities in inhalation and nasal drug development.

“I am excited to join Resyca at such a pivotal time in the evolution of inhaled and nasal drug delivery,” said Dr Jones. “Soft mist technologies represent a significant step forward in optimising drug deposition, improving ease of use, and enhancing dose consistency. With Resyca’s technologies, we can improve adherence, therapeutic effectiveness, and ultimately patient outcomes.”

About Resyca

Resyca® is redefining drug delivery with its next‑generation Soft Mist Inhalers and Soft Nasal Sprays. Founded in 2020 as a joint venture between Medspray and Bespak, Resyca develops advanced, proprietary delivery platforms that integrate Medspray’s micro‑nozzle technology.

With Resyca’s delivery devices, pharmaceutical partners can clearly differentiate their therapies through highly efficient pulmonary delivery and precise nasal administration—making Resyca’s platforms an excellent fit for a broad spectrum of drug–device combination products.

To further accelerate development and commercialisation, Resyca supports pharmaceutical partners with a comprehensive suite of services spanning early‑stage development through to full commercial launch.

To learn more, please visit www.resyca.com.

The post Resyca Announces the Appointment of Deborah Jones as New CEO first appeared on Resyca.

Read the fact sheet to learn more.

The post Resyca® Soft Nasal Spray Adaptor: low shear forces and optimal nasal coverage first appeared on Resyca.

Download our fact sheet to discover the key benefits of the PFSI Soft Mist Inhaler.

The post Resyca® PFSI™ Soft Mist Inhaler (SMI): Inhalation spray in a convenient device first appeared on Resyca.

Download our fact sheet to discover the key benefits of the Pulmospray™ Soft Mist Inhaler.

The post Resyca® Pulmospray™ Soft Mist Inhaler (SMI): fast preparation and breath-synchronised delivery first appeared on Resyca.

Publication: ONdrug Delivery 180, 26th November 2025

Abstract: With the increasing demand for new inhalation therapies, the need for efficient, patient-centric and sustainable delivery platforms is paramount. The Resyca PFSI is uniquely positioned to meet these needs, enabling precise and reliable delivery of even the most fragile molecules.

Soft Mist Inhaler (SMI) technology is transforming inhaled drug delivery — making treatments more efficient, patient-friendly, and sustainable.

Key highlights from the article:

• Enhanced Usability: SMIs reduce coordination errors and improve lung deposition, supporting better outcomes for diverse patient groups.
• Compatibility with Biologics: Ideal for next-generation therapies like vaccines and gene therapies, where gentle aerosolisation is crucial.
• Innovation with PFSI™: Resyca’s Pre-Filled Syringe Inhaler sets new standards for precision dosing, scalability, and patient-centric design. PFSI – Soft Mist Inhaler SMI.

This innovation is paving the way for tailored dosing, improved treatment adherence, and cost-effective delivery—critical for biologics and high-value therapies.

The post Enhancing drug delivery with innovative soft mist inhaler technology first appeared on Resyca.

Journal: European Journal of Pharmaceutical Sciences, Volume 214, 2025

Abstract: Inhalable mRNA is an emerging field holding great potential for applications as mucosal vaccination, antiviral therapy or protein replacement therapies, but efficient delivery remains a bottleneck.

In this study, we explore the use of a Soft Mist Inhaler (SMI), based on Rayleigh-breakup, for pulmonary mRNA delivery. We found that the SMI successfully aerosolised GFP mRNA encapsulated in liposomes while maintaining colloidal stability, mRNA integrity and in vitro transfection efficiency in A549 cells. Furthermore, the device enabled simultaneous delivery of nucleic acids in various sizes using a model CRISPR/Cas13d system.

The formulation could be reproducibly aerosolised with a low geometric standard deviation (GSD) and optimal aerosol droplet size for lung delivery. Based on the aerosol data, lung deposition modeling was conducted, indicating high lung deposition with minimal exhaled fraction. In comparison, aerosolization by a conventional Vibrating Mesh Nebuliser led to significant loss of nanoparticles and transfection efficiency. Utilising SMIs may facilitate pulmonary delivery of mRNA nanoparticle formulations by lowering stability-associated hurdles while providing intrinsically high deposition in the lungs.

Reference

The post Soft mist inhaler nebulisation by Rayleigh-breakup largely preserves functional integrity of liposomal mRNA in respirable aerosols first appeared on Resyca.

Resyca is a joint venture between Bespak and Medspray. Bespak has a strong franchise and is an established supplier of inhalation devices to the pharma industry.

By having access to this proprietary device manufacturing line, Resyca can provide shorter time lines for new customers. The idea is that multiple customers will use the same device manufacturing platform with minor pre designed change options like the volume per actuation and the outer parts design, including colours and labeling. This way Resyca can achieve economies of scale for the soft mist inhaler platform, for multiple clients who separately would not have enough unit sales to justify the capital investments necessary.

The post Bespak – device manufacturing first appeared on Resyca.

Journal: International Journal of Pharmaceutics, Volume 683, 2025

Abstract: The COVID-19 pandemic has emphasised the need for innovative and efficient drug delivery systems, particularly for nucleic acid-based therapeutics.

Lipid nanoparticle (LNP)-based small interfering RNA (siRNA) technology provides a promising strategy for gene therapy, immune modulation, and targeted molecular medicine. Intranasal delivery of LNP-siRNA formulations offers advantages such as efficient gene silencing and non-invasive administration.

However, the nasal spray device plays a crucial role in determining the deposition patterns within the nasal cavity and can impact the physicochemical stability of LNP formulations during aerosolisation. In this study, the Rayleigh Jet Nasal Atomiser was evaluated for its performance in delivering three LNP-siRNA formulations designed based on the LNP structures of Moderna, Pfizer, and Alnylam (Onpattro) marketed formulations, respectively.

Key nanoparticle characteristics, including particle size distribution, polydispersity index (PDI), zeta potential, and encapsulation efficiency, as well as aerosol properties such as droplet size, were analyzed before and after aerosolisation. Deposition patterns were assessed using the Alberta Idealized Nasal Inlet (AINI) model to determine the distribution of aerosolized LNPs. The results demonstrate that the Rayleigh Jet Nasal Atomizer efficiently delivers all the three formulations to the nasal cavity, primarily targeting the nasopharynx, while minimizing deposition in the lower respiratory tract.

Additionally, the device maintained LNPs structural integrity, although a reduction in encapsulated siRNA concentration suggests partial LNP disruption during aerosolisation. These findings indicate that the Rayleigh Jet Nasal Atomiser is a suitable device for intranasal delivery of LNP-based siRNA therapeutics, offering a promising approach for nasal administration of RNA-based drug delivery.

Reference

The post Evaluation of Rayleigh jet atomiser for intranasal delivery of lipid nanoparticle – siRNA formulations: stability, deposition, and device performance first appeared on Resyca.

Journal: Journal of Drug Delivery Science and Technology, Volume 115, Part 1, 2026

Abstract: Pulmonary delivery of mRNA-lipid nanoparticles (mRNA-LNPs) offers a promising non-invasive route of administration for pulmonary gene therapy, vaccine applications, amongst others.

However, aerosolisation can compromise nanoparticle stability, affecting its payload and thus delivery efficiency. This study evaluates the impact of aerosolisation via Rayleigh breakup and Savart impinging jet-based SMIs and various mesh nebulisers in preserving mRNA-LNP integrity and thus optimising pulmonary deposition.

The PFSI (Resyca) and Respimat (Boehringer Ingelheim) SMIs, as well as the Innospire Go and Pari eFlow mesh nebulisers were assessed for their impact on LNP particle size, zeta potential, encapsulation efficiency, and mRNA stability.

The PFSI SMI maintained mRNA-LNP physicochemical properties with minimal aggregation and superior encapsulation efficiency, while the other devices induced significant particle alterations and mRNA degradation.

These findings highlight the potential of SMIs, particularly the PFSI device, for inhaled mRNA-LNP delivery. Its ability to maintain nanoparticle stability warrants clinical evaluation.

Reference

The post Rayleigh-based soft mist inhalers preserve mRNA-LNP integrity for pulmonary delivery first appeared on Resyca.

This recertification underscores our commitment to maintaining the highest standards in quality management and regulatory compliance.

Since obtaining our initial certification in 2022, we have continuously expanded and strengthened our quality framework, achieving additional certifications, including compliance with the Medical Device Regulation (MDR). These milestones reflect our dedication to ensuring robust processes that align with regulatory requirements, enabling us to develop and deliver innovative soft mist inhalers and drug delivery solutions.

This achievement would not have been possible without the outstanding efforts of our team. Special thanks to Dr. Raimund Gleixner, Danish Mairaj, and everyone involved for their expertise and dedication in managing and improving our quality system.

At Resyca, we remain committed to excellence in inhalation drug delivery and will continue to drive innovation while meeting the highest regulatory and quality standards.

Download Certificate

About Resyca®

Resyca® was founded in 2020 and is a joint venture between Bespak and Medspray. Resyca® specialises in the development and manufacturing of compact, user-friendly soft mist inhalation and soft nasal spray devices, incorporating the proprietary Medspray micro-nozzle technology. These devices are tailored for pulmonary and nasal applications, utilising standard pre-filled syringes / primary packaging and filling lines. As the soft mist development centre within Bespak, Resyca offers comprehensive services spanning from early-stage development through to commercial production, inclusive of filling, labelling, and packaging.

For further information and interview opportunities with Resyca®, please contact:

Bernhard Müllinger at Resyca BV
Email: info@resyca.com
Website: www.resyca.com

The post Resyca BV successfully recertified for ISO 13485 – valid until 2028 first appeared on Resyca.